Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Dual/triple agonist, Other, Topics Aug 22 | 2018Novo Partners for Early Stage Small Molecule DevelopmentPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Topics Aug 21 | 2018Medtronic CY Q2 ’18 (FY Q1 ’19) Earnings UpdatePurchase Blast
$599
Posted in: GLP-1RA, Topics Aug 20 | 2018Oral semaglutide shows superiority in renal impairment patients (PIONEER 5)Purchase Blast$599
Posted in: Basal Insulin, Topics Aug 17 | 2018Novo acquires Ziylo for glucose responsive insulin developmentPurchase Blast
$599
Posted in: Glucagon, Insulin Delivery, Topics Aug 17 | 2018Diabetes Tech Update: Xeris, Tandem, and VoluntisPurchase Blast
$599
Posted in: Basal Insulin, Topics Aug 16 | 2018Tresiba label update - Anti-drug Ab data addedPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Topics Aug 09 | 2018Medtronic Launches 670G & Guardian Connect Gamification AppPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Topics Aug 09 | 2018ADA Releases Position Statement for T1DM Peds CarePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Other, Topics Aug 09 | 2018Novo Q2 ’18 London Earnings EventPurchase Blast
$599
Posted in: Glucose Monitoring, Topics Aug 08 | 2018SENS: Roche Acquisition Possible; Senseonics Q2 ’18 Earnings UpdatePurchase Blast$599
Posted in: Glucagon, Topics Aug 08 | 2018Glucagon: New Xeris Market Survey Detailed in Investor PPTPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Insulin Delivery, Topics Aug 08 | 2018Novo Q2 ’18 Earnings UpdatePurchase Blast
$599
Posted in: Glucose Monitoring, Other, Topics Aug 07 | 2018ESI 2019 Formulary Exclusions; No Diabetes Drug ChangesPurchase Blast
$599
Posted in: Glucose Monitoring, Topics Aug 07 | 2018Senseonics Launches Eversense Implantable CGMPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucagon, Other, Topics Aug 07 | 2018New Novo Ph1 Oral Peptide?Purchase Blast